Experienced in Adenoid Cystic Carcinoma

Dr. Doris V. Quon

Hematology
403 West Adams Boulevard, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Adenoid Cystic Carcinoma
403 West Adams Boulevard, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Doris Quon is a Hematologist in Los Angeles, California. Dr. Quon is rated as an Experienced provider by MediFind in the treatment of Adenoid Cystic Carcinoma. Her top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, and Hemophilic Arthropathy. Dr. Quon is currently accepting new patients.

Her clinical research consists of co-authoring 56 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Adenoid Cystic Carcinoma.

Specialties
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MercyCare
  • EPO
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

403 West Adams Boulevard, Los Angeles, CA 90007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Enrollment Status: Recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drug: Coagulation factor VIIa [recombinant]-jncw
Study Phase: Phase 4
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Drug, Procedure
Study Drugs: Pegylated arginine deiminase, Gemcitabine, Docetaxel
Study Phase: Phase 2
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: BAX-888 Adeno-Associated Virus Serotype 8 Vector B-Domain Deleted Factor VIII Vaccine
Study Phase: Phase 1/Phase 2
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
A Phase 1/2 Study Using Nivolumab and ABI-009 for Advanced Sarcoma, Advanced Carcinoma Treated With PD1 Inhibitors, and Tumors With Genetic Mutations Sensitive to mTOR Inhibitors
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Nab-Rapamycin, Nivolumab
Study Phase: Phase 1/Phase 2
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
Enrollment Status: Terminated
Publish Date: July 19, 2024
Intervention Type: Biological
Study Phase: Phase 1
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Genetic
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 2
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
An Observational Cohort Study of Long-Term Outcomes of Orthotopic Liver Transplantation in People With Hemophilia
Enrollment Status: Completed
Publish Date: May 10, 2023
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study With a Long-Term, Open-Label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients With Hemophilic Arthropathy
Enrollment Status: Terminated
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drug: TRM-201
Study Phase: Phase 3
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (ADVATE rAHF-PFM): A Phase 4 Study to Determine the Pharmacokinetic Response of Patients Diagnosed With Severe Hemophilia A to Different Doses of ADVATE rAHF-PFM
Enrollment Status: Completed
Publish Date: June 10, 2021
Intervention Type: Biological
Study Phase: Phase 4
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

55 Total Publications

Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: February 13, 2025
Similar Doctors
Distinguished in Adenoid Cystic Carcinoma
Dr. Victoria M. Villaflor
Oncology | Hematology
Distinguished in Adenoid Cystic Carcinoma
Dr. Victoria M. Villaflor
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (27.5 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Victoria Villaflor is an Oncologist and a Hematologist in Orange, California. Dr. Villaflor is rated as a Distinguished provider by MediFind in the treatment of Adenoid Cystic Carcinoma. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Salivary Gland Tumors, Gastrostomy, and Tissue Biopsy.

Advanced in Adenoid Cystic Carcinoma
Dr. Kalust Ucar
Hematology
Advanced in Adenoid Cystic Carcinoma
Dr. Kalust Ucar
Hematology

Kalust Ucar, MD Private Practice

222 W Eulalia St, Ste 100B, 
Glendale, CA 
 (6.9 miles away)
818-637-7611
Languages Spoken:
English, Armenian, French, Portuguese, Spanish
See accepted insurances
Offers Telehealth

Kalust Ucar is a Hematologist in Glendale, California. Dr. Ucar is rated as a Distinguished provider by MediFind in the treatment of Adenoid Cystic Carcinoma. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Advanced in Adenoid Cystic Carcinoma
Dr. Rupali K. Nabar
Oncology | Hematology
Advanced in Adenoid Cystic Carcinoma
Dr. Rupali K. Nabar
Oncology | Hematology

Uc Regents

101 The City Dr S, 
Orange, CA 
 (27.5 miles away)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rupali Nabar is an Oncologist and a Hematologist in Orange, California. Dr. Nabar is rated as a Distinguished provider by MediFind in the treatment of Adenoid Cystic Carcinoma. Her top areas of expertise are Laryngeal Cancer, Squamous Cell Skin Carcinoma, Bone Tumor, and Teratocarcinosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Quon's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile